BioLineRx (NASDAQ: BLRX) CEO details 5.1M shares and multiple option grants

Rhea-AI Filing Summary

BioLineRx Ltd. Chief Executive Officer Philip A. Serlin filed an initial ownership report detailing his equity position. He directly holds 5,131,800 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with exercise prices ranging from $0.2640 down to $0.0450, expiring between 2026 and 2033. Several option grants are fully vested, while the most recent grant includes options that will vest in quarterly installments, subject to his continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Serlin Philip A

(Last) (First) (Middle)

BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, 0.1 NIS per share	5,131,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/10/2017	10/10/2026	Ordinary Shares	55,800(9)	$0.264	D
Employee Stock Option (Right to Buy)(1)(3)	07/05/2018	07/05/2027	Ordinary Shares	316,200(9)	$0.284	D
Employee Stock Option (Right to Buy)(1)(4)	12/26/2018	04/16/2028	Ordinary Shares	719,400(9)	$0.285	D
Employee Stock Option (Right to Buy)(1)(5)	03/25/2020	11/07/2029	Ordinary Shares	1,136,400(9)	$0.287	D
Employee Stock Option (Right to Buy)(1)(6)	11/17/2021	04/05/2031	Ordinary Shares	3,301,200(9)	$0.152	D
Employee Stock Option (Right to Buy)(1)(7)	03/15/2023	08/15/2032	Ordinary Shares	4,194,600(9)	$0.102	D
Employee Stock Option (Right to Buy)(1)(8)	03/21/2024	09/06/2033	Ordinary Shares	4,495,200(9)	$0.045	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is October 10, 2016. This option grant is fully vested as of this date.

3. The grant date of this grant is July 05 ,2017. This option grant is fully vested as of this date.

4. The grant date of this grant is April 16, 2018. This option grant is fully vested as of this date.

5. The grant date of this grant is November 07, 2019. This option grant is fully vested as of this date.

6. The grant date of this grant is April 05, 2021. This option grant is fully vested as of this date.

7. The grant date of this grant is August 15, 2022. This option grant is fully vested as of this date.

8. The grant date of this grant is September 06, 2023. As of this date, 3,090,600 options of this grant are vested. The remaining 1,404,600 options will vest in equal 5 quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

9. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

	/s/ Philip Serlin	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioLineRx (BLRX) CEO Philip Serlin report in this Form 3?

Philip Serlin reports his initial ownership of BioLineRx securities, including 5,131,800 Ordinary Shares and multiple employee stock option grants. These options cover Ordinary Shares at various exercise prices and expirations, giving a detailed snapshot of his current equity-based compensation position.

How many BioLineRx Ordinary Shares does the CEO directly hold according to the filing?

The CEO directly holds 5,131,800 Ordinary Shares of BioLineRx. This figure represents his reported direct share ownership as of the Form 3 filing date, separate from his employee stock options, which provide additional potential equity exposure if exercised in the future.

What stock options for BioLineRx (BLRX) does the CEO report holding?

The CEO reports multiple Employee Stock Options over Ordinary Shares with exercise prices such as $0.2640, $0.2840, and $0.0450. These options expire between 2026 and 2033, reflecting grants made over several years under the company’s share incentive plan.

Are the BioLineRx CEO’s stock options vested according to the Form 3 footnotes?

Footnotes state that several option grants from 2016 through 2022 are fully vested. The September 6, 2023 grant is partially vested, with remaining options vesting in equal quarterly installments, contingent on the CEO’s continued service to BioLineRx on each vesting date.

Under which plan were BioLineRx (BLRX) CEO stock options granted?

The filing notes that the options were granted under the 2003 Amended and Restated Share Incentive Plan. Footnotes also explain that, to qualify for Israeli Section 102 tax benefits, related securities must be registered in the name of a trustee on behalf of the employee.

Does this BioLineRx Form 3 show new share purchases or sales by the CEO?

The Form 3 serves as an initial ownership report and lists holdings rather than new open-market purchases or sales. It details existing Ordinary Share ownership and outstanding employee stock options but does not record buy or sell transactions in the reported entries.